Paediatric formulation of fosamprenavir approved in the US

On 14 June 2007, the Food and Drug Administration approved a new formulation of Lexiva. Lexiva (fosamprenavir calcium) is now available as an oral suspension (50-mg/mL).

The package insert was updated to include information on this new formulation and to provide dosing information for pediatric patients and patients with hepatic impairment.

For full prescribing information see the product information:

Source: FDA list serve

Links to other websites are current at date of posting but not maintained.